09:55 AM EST - Paladin Labs Inc. : today announced that the Superior Court of Québec has issued on August 26, an interim order authorizing Labopharm Inc., among other things, to call, hold and conduct a special meeting of its shareholders to consider and, if deemed advisable, pass a special resolution approving an arrangement under section 414 of the Business Corporations Act (Québec) pursuant to which Chimigen Inc., a wholly-owned subsidiary of Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash. Paladin Labs Inc.
shares T.PLB are trading down $0.94 at $36.00.
